癌症
药物发现
医学
计算生物学
生物信息学
生物
内科学
作者
Yongji Zeng,A. Craig Lockhart,Ramon U. Jin
标识
DOI:10.1080/17460441.2024.2370332
摘要
Gastric cancer remains a formidable challenge in oncology with high mortality rates and few advancements in treatment. Claudin-18.2 (CLDN18.2) is a tight junction protein primarily expressed in the stomach and is frequently overexpressed in certain subsets of gastric cancers. Targeting CLDN18.2 with monoclonal antibodies, such as zolbetuximab (IMAB362), has shown promising efficacy results in combination with chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI